Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving transferase
Reexamination Certificate
1999-11-23
2001-10-09
Prouty, Rebecca E. (Department: 1642)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving transferase
C435S025000, C435S007100, C435S193000, C435S189000
Reexamination Certificate
active
06300092
ABSTRACT:
BACKGROUND OF THE INVENTION
Lysyl oxidase (“LOX”) is an extracellular copper enzyme that initiates the crosslinking of collagens and elastin by catalyzing oxidative deamination of the &egr;-amino group in certain lysine and hydroxylysine residues of collagens and lysine residues of elastin (Smith-Mungo and Kagan (1998)
Matrix Biol.
16:387-398 and Kaman in
Biology of Extracellular Matrix,
ed. Mecham (1986)
Academic Press
pp. 321-389). Lysyl oxidase has been shown to be important in a variety of cellular and physiologic processes including biogenesis of connective tissue matrices and bone resorption. A deficiency in lysyl oxidase activity is found in two X-linked, recessively inherited connective tissue disorders, the type IX variant of the Ehlers-Danlos syndrome and the Menkes syndrome, and in the X-linked, recessively inherited mottled series of allelic mutant mice (all characterized by abnormalities in copper metabolism). (Byers et al. (1980)
New Engl. J. Med.
303:61-65; Royce et al. (1980)
Biochemistry J.
192:579-586; Kuivaniemi et al. (1982)
J. Clin. Invest.
69:730-733; Kuivaniemi et al. (1985)
Amer. J. Human. Genet.
37:798-808; Peltonen et al. (1983)
Biochemistry
22:6156-6163; Rowe et al. (1977)
J. Biol. Chem.
252:939-942; Starcher et al. (1977)
Biochem. Biophys. Res. Commun.
78:706-712; Danks in
The Metabolic Basis of inherited Disease”, eds. Stanbury et al. (
1983),
McGraw-Hill
pp. 1251-1268). Increased lysyl oxidase activity has been associated with fibrotic disorders such as atherosclerosis, hypertension, and liver and pulmonary fibrosis. (Kagan, supra).
More recently there have been identified proteins having structural and/or functional similarities to lysyl oxidase. For example, a lysyl oxidase-like protein, referred to herein as “LOL”, was identified from a human skin fibroblast cDNA library that contains extensive homology to several coding domains within the human lysyl oxidase mRNA which is believed to be involved in collagen maturation. (Kenyon et al. (1993)
J. Biol. Chem.
268:18435-18437 and Kim et al. (1995)
J. Biol. Chem.
270:7176-7182). Recent cloning and analysis of the mouse LOL gene (Kim et al. (1999)
J. Cell Biochem.
72:181-188) demonstrated that steady state levels of LOL mRNA and type III procollagen mRNA increased coincidentally early in the development of liver fibrosis. In contrast, steady state levels of lysyl oxidase mRNA increased throughout the onset of hepatic fibrosis and appeared in parallel with the increased steady state levels of pro-alpha (I) collagen mRNA, suggesting that the LOL protein is involved in the development of lysine-derived cross-links in collagenous substrates. Moreover, the substrate specificity of the LOL protein may be different to that of lysyl oxidase and this difference may be collagen-type specific.
Likewise, a protein referred to herein as lysyl-oxidase related protein (“Lor”) has been identified which inhibits many of the structural features of lysyl oxidase and is overexpressed in senescent fibroblasts and is believed to play a role in age-associated changes in extracellular proteins. (Saito et al. (1997)
J. Biol. Chem.
272:8157-8160). Lor contains four domains referred to herein as scavenger receptor cysteine-rich domains (“SRCR domains”) which are believed to be involved in binding to other cell surface proteins or extracellular molecules. The SRCR domain joins a long list of other widely distributed cysteine-containing domains found in extracellular portions of membrane proteins and in secreted proteins (Doolittle (1985)
Trends Biochem. Sci.
10:233-237; Krieger in
Molecular Structures of Receptors,
eds. Rossow et al. (1986)
Horwood, Chichester,
U.K pp. 210-231). Examples include the EGF-like domain, immunoglobulin superfamily domains, the LDL receptor/complement. C9 domain, clotting factor Kringle domains, and fibronectin domains. These disulfide cross-linked domains appear to provide stable core structures that (i) are able to withstand the rigors of the extracellular environment; (ii) are well suited for a variety of biochemical tasks, often involving binding; and (iii) are readily juxtaposed to other types of domains to permit the construction of complex mosaic proteins. (Doolittle supra; Sudhof et al. (1985)
Science
228:815-822). Lastly, a mouse cDNA encoding a putative protein having sequence homology to lysyl oxidase has recently been identified having the Accession No. AF053368, referred to herein as “Lor-2”.
Lysyl oxidases (“LOXs”) have been immunolocalized to the extracellular matrix regions of stroma surrounding early breast cancers (Decitre et al. (1998)
Lab Invest.
78:143-151), with decreased expression observed in the stroma surrounding invasive breast cancers (Peyrol et al. (1997)
Am. J. Pathol.
150:497-507). A progressive loss of LOX expression has also been observed during prostrate cancer progression in mice (Ren et al. (1998)
Cancer Res.
58:1285-1290). These observations suggest that lysyl oxidases may function as tumor suppressors.
It has further been shown that human Lor is highly expressed in all adherent tumor cell lines examined, but not in cell lines that grow in suspension (Saito et al., supra), suggesting that LOXs can increase the adhesion properties of tumor cells. Lor expression was demonstrated to be concomitant with upregulation of type I procollagen. As adhesion properties contribute to the ability of tumor cells to colonize new sites, a tumor-promoting role for LOXs is also probable.
A greater understanding of the role which lysyl oxidase-like as well as SCRC domain containing proteins play in various disorders would lead to the determination of highly specific drug targets which would work to treat these disorders, e.g., cardiovascular disorders, a disorder arising from altered lysyl oxidase-like activity or a disorder arising from improperly regulated SRCR-domain containing protein activity giving rise to improperly regulated cellular processes.
SUMMARY OF THE INVENTION
The present invention is based, at least in part, on the discovery of novel nucleic acid molecules and proteins encoded by such nucleic acid molecules, referred herein as
L
ysyl
O
xidase
R
elated-2 (“Lor-2”) molecules. The Lor-2 nucleic acid and protein molecules of the present invention are useful as modulating agents in regulating a variety of cellular processes (e.g., cellular processes in the cardiovascular system, for example, cardiac cellular processes). The Accordingly, in one aspect, this invention provides isolated nucleic acid molecules encoding Lor-2 proteins or portions thereof, as well as nucleic acid fragments suitable as primers or hybridization probes for the detection of Lor-2-encoding nucleic acids. In another embodiment, an isolated nucleic acid molecule of the present invention preferably encodes a Lor-2 protein which includes a signal sequence and/or is secreted. In yet another embodiment, an isolated nucleic acid molecule of the present invention preferably encodes a Lor-2 protein which lacks a signal sequence and/or is intracellular.
In one embodiment, a Lor-2 nucleic acid molecule of the invention is at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more homologous to a nucleic acid sequence (e.g., to the entire length of the nucleotide sequence) having the nucleotide sequence shown in SEQ ID NO:1 or a complement thereof.
In a preferred embodiment, the isolated nucleic acid molecule includes the nucleotide sequence shown in SEQ ID NO:1, or a complement thereof. In another embodiment, the nucleic acid molecule includes nucleotides 143-2401 shown in SEQ ID NO:1. In another preferred embodiment, the nucleic acid molecule has the nucleotide sequence shown in SEQ ID NO:1. In another preferred embodiment, the nucleic acid molecule comprises a fragment of at least 50 contiguous nucleotides of the nucleotide sequence shown in SEQ ID NO: 1, or a complement thereof.
In another embodiment, a Lor-2 nucleic acid molecule includes a nucleotide sequence encoding a protein having an amino acid sequence at least ab
Khodadoust Mehran M.
MacBeth Kyle J.
Lahive & Cockfield LLP
Mandragouras Amy E.
Milasincic Debra J.
Millennium Pharmaceuticals Inc.
Prouty Rebecca E.
LandOfFree
Methods of use of a novel lysyl oxidase-related protein does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of use of a novel lysyl oxidase-related protein, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of use of a novel lysyl oxidase-related protein will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2581926